Oxalic acid
|
Basic information |
| Metabolite name | Oxalic acid |
 | HMDB0002329 |
 |
C00209 |
 |
971 |
| Synonyms | oxalate; |
| No. of studies | 13 |
|
Basic information |
| Metabolite name | Oxalic acid |
| HMDB0002329 |
|
C00209 |
|
971 |
| Synonyms | oxalate; |
| No. of studies | 13 |
|
Relationship between Oxalic acid and depression (count: 13) |
| Study | Study Type  |
Comparison groups | Tissue | Organism | Up/Down regulated |
| Study M004 | Type2 | CUMS + amitriptyline group vs. CUMS group | Urine | Sprague-Dawley rat | Up |
| Study M004 | Type2 | CUMS + xiaoyaosan group vs. CUMS group | Urine | Sprague-Dawley rat | Up |
| Study M075 | Type1 | post stroke depressed group vs. post stroke non-depressed group | Plasma | Human | Down |
| Study M129 | Type3 | venlafaxine group vs. control group | Hippocampus | C57BL/6J mouse | Down |
| Study M181 | Type3 | venlafaxine group vs. control group | Prefrontal cortex | Sprague-Dawley rat | Up |
| Study M181 | Type3 | venlafaxine group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M463 | Type3 | venlafaxine group vs. control group | Prefrontal cortex | C57BL/6J mouse | Down |
| Study M492 | Type1 | ACTH group vs. control group | Urine | Wistar rat | Down |
| Study M492 | Type2 | ACTH + memantine group vs. ACTH group | Urine | Wistar rat | Up |
| Study M492 | Type2 | ACTH + CGA group vs. ACTH group | Urine | Wistar rat | Up |
| Study M610 | Type1 | CUMS group vs. control group | Liver | Sprague-Dawley rat | Up |
| Study M613 | Type2 | CSDS susceptible + imipramine group vs. CSDS + vehicle group | Ventral hippocampus | C57BL/6 J mouse | Down |
| Study M613 | Type2 | CSDS susceptible + imipramine group vs. CSDS + vehicle group | Serum | C57BL/6 J mouse | Down |
| Study M635 | Type1 | depression group vs. control group | Plasma | Human | Up |
| Study M635 | Type2 | depression group, after vs. before Xiaoyaosan treatment | Plasma | Human | Down |
| Study M648 | Type1 | ART-treated HIV with depressive symptom group vs. ART-treated HIV without depressive symptom group, discovery cohort | Plasma | Human | Down |
| Study M663 | Type3 | diterpene ginkgolides group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M843 | Type1 | CUMS group vs. control group | Faece | Cynomolgus monkey | Down |
| Study M870 | Type2 | CRS + sertraline group vs. CRS group | Brain | C57BL/6 mouse | Up |